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Introduction
Understanding the role the immune system in the host
defense against cancer is fundamental for both present
and future attempts of anti-cancer immunotherapy.
Dendritic cells (DCs) are among the most effective
immune response activators. The main function of
immature DCs is antigen recognition, internalization,
and its intracellular processing. Immature DCs circu-
lating in the blood survey peripheral tissues and are
recruited to inflammatory sites for antigen uptake.
Antigen-loaded DCs gain the ability to migrate
through lymphatics into draining lymphoid tissues
[1,2]. During migration, DCs may activate naive T
lymphocytes [3] which, after differentiation, acquire
the ability to migrate from the lymph node to an
inflammatory site. 
It has been demonstrated that exogenous DCs
loaded with a tumor-specific antigen effectively
prime T cells [4,5]. In animal tumor models, DCs
loaded with tumor antigen induced anti-tumor
response and even a regression of established tumor
[6]. However, clinical trials of anti-cancer
immunotherapy with antigen-loaded DCs varied and
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Abstract: The recognition, internalization and intracellular processing of antigen are the main functions of dendritic cells
(DCs). In the course of these processes, DCs differentiate and acquire the ability to produce cytokines responsible for polar-
ization of the immunological response. Therefore, vaccination with tumor antigen-loaded DCs is one of the most promising
approaches to induce tumor-specific immune response. The purpose of this study was to analyze the migratory abilities,
from an injection site to tumor-draining lymph nodes (tLN), of DCs applied as an anti-tumor vaccine and their capacity for
immune response activation. Mouse DCs of the established JAWS II cell line transduced with EGFP gene or ex vivo bone
marrow-isolated DCs (BM-DCs) stained with intravital CFDA dye were loaded with MC38 colon carcinoma tumor lysate
(TAg) and then administered peritumorally to MC38 tumor-bearing C57BL/6 mice. On the first, third, fifth and seventh days
after injection the tumors, tLNs and spleens were examined. The TAg-loaded DCs migrated more effectively to the tLNs
than did the unloaded control DCs; however, the majority of them remained in the tumor vicinity. Immunohistological analy-
sis of the tumor tissues demonstrated that only TAg-loaded DCs activated an immune response. Seven days after DCs vac-
cine administration, numerous necrotic areas and some apoptotic bodies were observed in the tumor tissue. However, the
anti-MC38 tumor cytotoxic activity of spleen and tLN cells from mice treated with both TAg-loaded and unloaded DCs
reached a maximum on the fifth day after DC injection. Concluding, TAg-loaded DCs migrated more efficiently to tLNs and
were more effective activators of local (but not systemic) cellular immune response than were unloaded DCs. We hypothe-
size that only the application of TAg-loaded DCs to tumor-bearing mice as an adjuvant supporting chemotherapy may acti-
vate a more effective anti-tumor response.
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were less successful than expected [7]. It seems that
much is still to be learned about DCs in vivo behav-
ior and the factors that control their ability to induce
an effective immune response.
In this study a detailed analysis of the migratory
capacities of peritumorally injected DCs loaded with
MC38 colon carcinoma tumor lysates (TAg-loaded
DCs) was performed. To determine whether TAg-
loaded DCs are efficient activators of immune
response, the effector activities of spleen and tumor-
draining lymph node (tLN) cells as well as MC38
tumor tissue infiltration with immune cells were esti-
mated. 
Materials and methods
Mice. The experiments were performed using 6- to 8-week-old
female C57BL/6 mice which were finally sacrificed according to
properly established protocols and government regulations (per-
mission of the Local Ethics Committee, 2004).
Cell culture. RPMI 1640 culture medium (Gibco) was supple-
mented with 100 U/mL penicillin, 100 U/mL streptomycin, 2
mmol/L L-glutamine, 1 mmol/L sodium pyruvate, and 50 μmol/L
2-mercaptoethanol (complete medium, CM). Cell of an established
mouse colon carcinoma cell line (MC38/0) [8] were cultured in
CM supplemented with 5% FCS. C57BL/6 mouse bone marrow-
derived dendritic cells of the JAWS II line (ATCC Cat. No. CRL-
11904) were maintained in a 1:1 mixture of alpha MEM (Gibco)
and CM supplemented with 10% FCS and 5 ng/mL GM-CSF
(Strathman). JAWS II cells transduced with a retroviral vector car-
rying enhanced green fluorescent protein gene (EGFP) and neor
gene as a selection marker (JAWS II/EGFP) were maintained
under the same culture conditions as the JAWS II cells. 
Generation of bone marrow-derived DCs (BM-DCs). Briefly,
the long bones of the female C57BL6 mice were dislodged and the
remaining tissue and muscles were removed with sterile gauze.
The ends of the bones were cut with sterile scissors and the bone
marrow was flushed from the femurs and tibias with 5% RPMI.
The bone marrow was washed three times and the cells were re-
suspended in CM supplemented with 10% (v/v) FCS. The cells
were cultured in 75-cm2 flasks at a concentration of 8×106 cells
per flask in 10 ml of 10% CM supplemented with 40 ng/mL recom-
binant murine GM-CSF and IL-4. The source of mouse IL-4 was
X63mIL4 plasmacytoma cell supernatant used in a concentration
of 5-10%, corresponding to 100 U/ml. The CM was replaced every
second day. After six days the BM-DCs were used for further tests. 
DCs stimulation with tumor antigen. MC38/0 lysate (called here
tumor antigen: TAg) was prepared by five cycles of freezing in liq-
uid nitrogen and thawing at 37°C. Then the mixture was sonicated
for two hours. The lysate was frozen and stored at -20°C. Imma-
ture DCs (BM-DCs and/or JAWS II/EGFP cells) were seeded in 75
cm2 flasks and then loaded with TAg for 24 hours (0.1 ml of TAg
was added to 1 ml cell suspension). After antigen loading, the BM-
DCs were stained with intracellular dye CFDA (Molecular Probes)
according to the producer's protocol at a concentration of 5
μmol/L. 
Mice-treatment schedule. The C57BL/6 mice were inoculated
subcutaneously (s.c.) with MC38 tumor cells (1.2×106 in 0.2
ml/mouse). After 14 days, the tumor-bearing mice received the
TAg-loaded DCs (JAWS II/EGFP/TAg or BM-DCs/CFDA/TAg)
vaccine. Unloaded JAWS II/EGFP and BM-DCs/CFDA cells
were used as negative controls. The DC vaccines were injected
peritumorally (p.t., 1×106 cells/0.2 ml/mouse). On the first, third,
fifth, and seventh days after DC injection the mice were killed
and the tumors, tumor-draining lymph nodes (tLNs), and spleens
from the vaccinated mice were dissected. The tumors and tLN
fragments were snap frozen and stored at -70°C prior to cryo-sec-
tioning for immunohistological analysis. The remaining spleen
and tLN cells were suspended in PBS without Ca2+ and Mg2+
(PBS-) containing 2.5% FCS and used for immune cell subpopu-
lations characteristic studies or frozen for further restimulation
and cytotoxicity assays.
Flow cytometric analysis of cell-surface phenotype. For the
analysis of cell surface phenotype, isolated spleen and lymph node
cells were incubated with the monoclonal antibodies (mAbs) PE
anti-CD4, FITC anti-CD8, FITC anti-CD45, or mouse-anti-NK.1.1
and FITC-labeled rat anti-mouse antibodies (all BD Pharmingen).
The cells were stained for 45 min at 4°C in a direct test, and for 30
and 45 min in indirect test. The analysis was carried out using a
Becton Dickinson FACS Calibur apparatus with Cell Quest Soft-
ware.
Detection of apoptosis. Apoptosis was detected by the TUNEL
(TdT-mediated dUTP nick end labeling) method. Cryostate sec-
tions of the tumor tissues were fixed in 4% paraformaldehyde,
washed in PBS- for 30 min, permeabilized in a freshly prepared
0.1% Triton-X-100 - 0.1% sodium citrate solution for 2 min at 4°C,
and washed (2 × 5 min) with PBS-. Then the TUNEL reaction mix-
ture containing terminal transferase and FITC-16dUTP
(Boehringer Mannheim, Germany) was added to the sample and
incubated at 37°C in the dark for 60 min. After incubation, the
slides were washed three times with PBS-, embedded with anti-
fade, and analyzed.
Histological staining. Tumor tissue cryo-sections 5-10 μm thick,
were fixed in 4% paraformaldehyde (30 min at 4°C).
Determination of DC migration abilities. Cryosections of
lymph nodes and tumors were counterstained with propidium
iodide (PI, 2 μg/mL, Sigma) and the presence of green cells, JAWS
II/EGFP cells or BM-DCs/CFDA cells, was evaluated in a direct
test by fluorescence microscopy.
Hematoxylin and eosin staining: Cryosections of lymph nodes
and tumors were stained with hematoxylin and eosin and examined
by light microscopy. 
Detection of T cells: Cryosections of lymph nodes and tumors
were incubated overnight with rat anti-CD4 or rat anti-CD8 anti-
bodies (BD Pharmingen). The slides were then washed with PBS-
and incubated with goat anti-rat antibody conjugated with Alexa
Fluor 488 (Molecular Probes). After one-hour incubation, the
slides were washed and counterstained with PI (2 μg/mL). All flu-
orophore-labeled tissue sections were analyzed using a BioRad
MRC 1024 scanning confocal fluorescence microscope equipped
with LaserSharp software. Cryosections from three distinct parts of
tumor from each individual mouse were analyzed.
Cytotoxic assay and determination of IFN-γ and IL-4 produc-
tion by activated spleen cells. Spleen cells from vaccinated mice
were isolated and co-cultured (restimulated) for five days with mit-
omycin C-treated MC38 cells (50 μg mitomycinC/3×106 cells/mL
5% CM incubated 30 min in 37°C) in the presence of IL-2. The
source of mouse IL-2 was X63mIL-2 plasmacytoma cell super-
nantant used at a concentration of 3%, corresponding to 100 U/mL.
After five days of restimulation, the culture supernatants were col-
lected and stored at -20°C. The cytotoxicity of the spleen cells was
tested by flow cytometry. Target MC38/0 cells were stained with
DiOC18 lipophilic dye (Molecular Probes) for 30 min at 37°C and
then washed with PBS-. Spleen cells were incubated after restimu-
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lation with labeled target cells for four hours at 37°C at a 10:1 ratio
of effector to target cells. Then the cells were washed and dead
cells were stained with PI. Samples were analyzed by flow cytom-
etry on FACS Calibur using FL1 and FL3 filters. The percentage of
dead cells (PI-positive) among the DiOC18 labeled target cells was
calculated. 
To measure IFN-γ and IL-4 production by activated spleno-
cytes, commercially available ELISA kits (Pharmingen) were
used.
Results
Migratory ability of TAg-loaded DCs from 
an injection site to tumor-draining lymph nodes
Mouse colon carcinoma-bearing C57BL/6 mice were
injected peritumorally (p.t.) with TAg-loaded DCs:
BM-DCs stained with CFDA dye (hereinafter BM-
DCs/CFDA/TAg) or JAWS II cells transduced with
EGFP gene (JAWS II/EGFP/TAg). Unloaded JAWS
II/EGFP and BM-DCs/CFDA cells were applied as a
negative control. On the first, third, fifth, and seventh
days after injection of DCs, the tumors and tumor-
draining lymph nodes (tLNs) from each animal group
were dissected. The presence of green fluorescent DCs
was estimated by fluorescence microscopy (tLN and
tumors slides) and flow cytometry (tLN cells). It was
observed that DCs injected p.t. migrated to the tLNs
(Fig. 1). Furthermore, histological analysis revealed
the presence of DCs in tLNs already on the first day
after injection. The BM-DC/CFDA number (both
loaded and unloaded with TAg) evaluated by flow
cytometry increased gradually until the fifth day and
then decreased. In addition, the experiments showed
that the BM-DCs/CFDA/TAg cells migrated to the
tLNs more effectively than did the BM-DCs/CFDA
cells (118/106 and 72/106 total cells, respectively). The
numbers and percentages of BM-DCs/CFDA in tLNs
are presented in Table 1.
It was also considered whether all the p.t. injected
DCs migrated to the tLNs. Most of the DCs remained
in the vicinity of the tumor (Fig. 2) and survived at the
site of injection until the 7th day after vaccination.
This applied especially to JAWS II/EGFP/TAg, but
also unloaded JAWS II/EGFP cells. In contrast, after
that time only debris of injected BM-DCs was visible
in the vicinity of tumor.
Spleen and lymph node cell effector activity
after p.t. injection of TAg-loaded DCs
The next step in the investigation was to estimate the
percentages of T cells in dissected tLNs and spleens,
the cytotoxic activity of tLNs and spleen cells, and
their abilities to produce IFN-γ and IL-4 after TAg-res-
timulation in vitro. 
The percentage of CD4- and CD8-positive cells did
not change in tLNs or in spleens isolated between the
1st- and 7th days after DC injection compared with con-
trols (healthy and tumor-bearing mice untreated with
DCs, data not shown).
Interactions between DCs and T cells (CD4 or
CD8) were examined by confocal microscopy in tLN
cryo-sections labeled with anti-CD4 or anti-CD8 anti-
bodies. Both TAg-loaded and unloaded DCs interacted
with CD4 cells already on the 3rd day after DC injec-
tion (Fig. 3). Interaction between DCs and CD8 lym-
phocytes was not clearly visible. Due to the presence
of DC-T lymphocyte clusters in the tLN sections, the
efficacy of different DC-based vaccines in immune
response stimulation was further investigated. No sig-
nificant differences in the levels of immune response
activation were observed between animals which
received TAg-loaded or control DCs. In the experi-
ments, the cytotoxicity of restimulated tLN cells grad-
ually increased up to the 5th day after DC injection and
then dropped back to the initial level. Only after JAWS
II/EGFP cell injection did the cytotoxic activity of the
tLN cells stay at the same level up to the 7th day.
Regardless of these observations, BM-DCs/CFDA and
BM-DCs/CFDA/TAg appeared to be more efficient
activators of immune response than TAg-loaded and
unloaded JAWS II/EGFP cells. On the 5th day after
BM-DCs/CFDA cell injection, the average percentage
of tLN cell cytotoxicity reached 43%, whereas after
vaccination with BM-DCs/CFDA/TAg cells it reached
39%. Although the cytotoxic activity triggered by BM-
DCs/CFDA/TAg injection was lower than that initiat-
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Table 1. Efficiency of BM-DCs/CFDA migration from the vicinity of tumor to tumor-draining lymph nodes. Cytometric analysis of the
tumor-draining lymph node cell suspension was performed on the 1st, 3rd, 5th, and 7th days after injection of BM-DCs/CFDA cells. BM-
DCs/CFDA with green fluorescence were analyzed.
ed by BM-DCs/CFDA injection, it decreased at a
slower rate (amounting to 29% and 25% on the 7th day,
respectively). Unexpectedly, vaccines consisting of
JAWS II/EGFP or JAWS II/EGFP/TAg cells resulted
in significantly lower tLN cell cytotoxicity (23%)
compared with both types of BM-DC/CFDA cells.
Furthermore, injection of these cells evoked an incon-
siderable increase of tLN cell cytotoxicity over con-
trols (20% for untreated mice and 13.5% for healthy
mice). JAWS II/EGFP/TAg cells proved to be slightly
better activators of the immune response than JAWS II
cells (Fig. 4a).
The cytotoxicity of spleen cells was lower than that
of tLN cells (reaching a maximum of 25%), but their
tendency to change was similar to that observed in tLN
cells (Fig 4b). Vaccination with BM-DCs or JAWS II
cells resulted in only limited differences in the cyto-
toxicity of spleen cells and was not as distinct as that
observed in tLN cells.
Generally, cytotoxic activity was accompanied by
the immune cells' ability to produce IFN-γ (Fig 5a, 5b).
The maximum IFN-γ level (average: 40 ng/mL) was
detected in supernatants collected from cultures of res-
timulated tLN cells which were harvested on the 5th
day after BM-DCs/CFDA cell vaccination. The pro-
duction of IL-4 was slight and that of TNF-α was
undetectable.
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Fig. 1. MC38 tumor-draining lymph nodes 5 days after injection of
A. JAWS II/EGFP; B. JAWS II/EGFP/TAg; C. BM-DCs/CFDA;
D. BM-DCs/CFDA/TAg. Intracytoplasmic green fluorescence of
JAWS II/EGFP or BM-DCs/CFDA cells (loaded or unloaded with
TAg) and the red nuclei of all the cells located in lymph node
(stained with PI 2 μg/ml) are visible.
Fig. 2. Tumor tissue after p.t. injection of DCs-based vaccine.
Intracytoplasmic green fluorescence of JAWS II/EGFP or BM-
DCs/CFDA cells (loaded or unloaded with TAg) and also the red
nuclei of surrounding cells (stained with PI 2 μg/ml) are visible.
In the pictures the edge of the tumor tissue on the 7th day after
injection of A. JAWS II/EGFP; B. JAWS II/EGFP/TAg cells; 
C. BM-DCs/CFDA/TAg cells; and the 3rd day after injection 
D. BM-DCs/CFDA cells.
Fig. 3. Visualization of DC and CD4+ T-cell interactions. Tumor-
draining lymph node tissue sections were stained with anti-CD4
conjugated with Alexa fluor 546 (red). In the pictures are visible the
interaction of CD4 cells with DCs (green): A. JAWS II/EGFP cells;
B. JAWS II/EGFP/TAg cells; C. BM-DCs/CFDA cells and 
D. BM-DCs/CFDA/TAg cells. All on the 3rd day after DCs injection.
Histological and immunohistological analysis
of immune cells infiltrating tumor tissue
Analyses of lymphocyte influx into the connective tis-
sue surrounding the tumor tissue and the level of tumor
cell apoptosis were performed on the 7th day after DC
injection. Histological examination of 14-day-old
tumors (when nodules were already palpable under the
skin) revealed that they were compact and surrounded
by connective tissue nodules. In the tumor tissue the
closely adjacent tumor cells with well-developed con-
nective tissue crossing the whole tumor tissue were
present. There were also a few infiltrating CD8 and
CD4 cells in the connective tissue, but not between
tumor cells. Seven days after injection of BM-
DCs/CFDA/TAg and JAWS II/EGFP/TAg cells,
numerous necrotic areas and a few apoptotic bodies
appeared in the whole tumor tissue (Fig. 6b, c). This
observation was confirmed by the more specific
TUNEL technique (detection of characteristic DNA
fragmentation, Fig. 6 d-g). In addition, the infiltration
level of tumor tissue by CD4 and CD8 lymphocytes
was similar to that observed in control tumor tissue
and was stable (data not shown). On the other hand,
vaccination with BM-DCs/CFDA or JAWS II/EGFP
cells as well as with physiological saline did not result
in damage of the tumor tissue (Fig. 6a). 
Discussion
The main function of DCs is antigen uptake and its fur-
ther presentation to immune effector cells. During the
process, DCs leave an inflammation site and migrate
through lymphatic vessels to lymph nodes. During
migration the DCs change their morphological and
functional features and reach maturity, at which time
they can act as efficient activators of naive T cells. In
reply to antigen presentation and IL-12 production by
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Fig. 4. Cytotoxic activity of tLN (A) and spleen (B; splc) cells col-
lected from mice on the 3rd, 5th, and 7th days after injection of
DCs. The cells were restimulated in vitro with MC38 cells and
then the cytotoxic assay was performed by flow cytometry. To cal-
culate the mean and standard deviation three mice from each pre-
sented group were tested. % cyotoxicity - the percentage of dead
target MC38 cells.
Fig. 5. Production of IFN-γ and IL-4 by restimulated in vitro tLN
(A) and spleen (B) cells. The concentration of IFN-γ and IL-4 was
measured by ELISA in supernatants collected from the above res-
timulated tumor-draining lymph node (tLN) or spleen (splc) cells
after DC injection. To calculate the mean and standard deviation
three mice from each presented group were tested.
DCs, T cells acquire the ability for clonal expansion
and migration from lymph nodes to an inflammatory
site [1,2].
Detailed analyses of the migration of TAg-loaded
DCs, injected p.t. to MC38 colon carcinoma-bearing
mice, and their ability to activate a specific immune
response were performed in this study. In the experi-
ments, two types of murine DCs were applied: bone
marrow-derived DCs (BM-DCs), maintained ex vivo,
and cells of the JAWS II line, possessing features of
immature myeloid DCs. All cells were loaded with
antigen prepared from MC38/0 cell lysate (TAg). We
chose stimulating DCs with lysate because according
to generally accepted information, loading DCs with
whole tumor cell components should generate a T-cell
response (both CD4+ helper T cells and CD8+ CTL) to
tumor-associated antigens. In consequence, this may
reduce the possibility of a tumor escaping the host
immune response [9,10].
Our findings demonstrate that BM-DCs/CFDA
cells or JAWS II/EGFP cells (TAg-loaded as well as
unloaded) injected p.t. were able to migrate to tumor-
draining lymph nodes. Both histological and cytomet-
ric analysis revealed that these DCs appeared in tLNs
already on the first day after injection, reaching a max-
imum on the 5th day. Lapin [11] and Martin-Fontecha
[12] examined the number of DCs infiltrating mouse
popliteal LNs after DC injection into the footpad.
Maximal numbers of DCs were detected in the lymph
nodes between the second and fourth day after DC
injection. In contrast, when DCs were injected s.c. they
rapidly infiltrated the draining LN, achieving a maxi-
mum within 30 min and remained in the node for sev-
eral hours [13]. The observed differences in the kinet-
ics of DC migration might be caused by the different
ways of DC injection. Therefore we suggest that p.t.
injection results in an initial sequestration and slower
efflux of DCs from an injection site to draining lymph
nodes. Moreover, immunosuppressive factors such as
IL-10, TGF-β, VEGF, or PGE2, often produced by
growing tumors, could have an additional negative
impact on DCs' migratory efficacy [14]. Consequently,
part of the injected DCs could be forced to remain in
the vicinity of the tumor (as observed in our experi-
ments). On the other hand, TAg-loaded DCs remaining
in the vicinity of tumor could be able to change a hos-
tile tumor environment and trigger a more efficient
anti-tumor response. 
Our observations also demonstrate that TAg-loaded
BM-DCs migrated to tLNs more effectively than
unloaded BM-DCs. Nevertheless, the number of the
cells in tLNs never exceeded 0.012%. Similar results
were obtained in experiments performed by Lappin et
al. [11]. Moreover, they observed the an increased
retention of DCs in LNs with increased number of
injected cells. However, Martin-Fontecha et al. [12]
noted that the number of infiltrating DCs reached a
plateau when the number of injected DCs was 2×106.
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Fig. 6. Apoptotic and necrotic cells in MC38 tumor tissue. Tumors were collected on the 7th day after DC injection. The tissue sections
were stained with H+E to analyze changes in tumor tissue structure (A-C) or stained with TUNEL reaction mixture containing terminal
transferaze and FITC-16dUTP to identify apoptotic cells (D-F). A. tumor tissue (TT) from untreated mouse (magnification × 400). In the
picture closely adjacent tumor cells with well-developed connective tissue containing fibroblasts are present; B. TT after injection of
JAWS II/EGFP/TAg cells (magnification × 400); C. TT after injection of BM-DCs/CFDA/TAg cells (magnification × 400); B-C: in the
whole tumor tissue, numerous necrotic areas and few apoptotic bodies are visible. Identification of apoptotic cells: D. positive control; 
E. negative control; F. apoptotic cells in tumor tissue after injection of JAWS II/EGFP/TAg cells; G: apoptotic cells in tumor tissue after
injection of BM-DCs/CFDA/TAg cells.
They suggest that the T-cell area of the LN may accept
only a limited number of exogenous cells. Alternative-
ly, DC infiltration may be limited by saturation of the
lymphatic vessels through which DCs migrate into the
T-cell areas of the LN. In our experiments, DC vac-
cines containing ca. 1×106 of cells were applied; there-
fore we supposed that the number of DCs retained in
tLNs could have been higher if we had injected a high-
er number of cells.
The next stage in our investigation was to evaluate
the possible interactions between DCs and T lympho-
cytes. It is well-known that exogenous antigens can
enter the MHC class I presentation pathway of APCs
and thereby prime CD8 T cells in a process generally
termed "cross-presentation" [15,16]. However, in our
experiments, DCs (TAg-loaded, but also unloaded
with TAg) made clusters with CD4 T cells, but inter-
actions between DCs and CD8 T cells were not clear-
ly visible. Because of this observation, spleen and tLN
cell effector activities as well as tumor tissue infiltra-
tion by immune cells were examined. BM-DCs/CFDA
cells, both loaded and unloaded with TAg, proved to be
more efficient immune response activators than JAWS
II/EGFP cells. They caused increased cytotoxicity of
spleen and lymph node cells and the ability to produce
IFN-γ compared with controls. Despite the lack of dif-
ferences in the cytotoxic activities of tLN or spleen
cells obtained from mice vaccinated with TAg-loaded
and unloaded DCs, changes in tumor tissue structure
were observed only after injection of TAg-loaded DCs
and only seven days after vaccination.
In conclusion, TAg-loaded DCs migrated more effi-
ciently to tLNs, and were more effective activators of
local (but not systemic) cellular immune response
compared with unloaded DCs. No significant differ-
ences between the effector activities of spleen and tLN
cells, regardless of the type of vaccine applied, were
observed. This presumably resulted from the way of
injection, because DCs injected in the vicinity of a
growing tumor had direct access to tumor antigen and
thus the host response evoked by both TAg-loaded and
unloaded DCs could be similar. We hypothesize that
only the application of TAg-loaded DCs to tumor bear-
ing mice as an adjuvant supporting chemotherapy may
activate a more effective anti-tumor response.
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